|
|
 |
|
Viewing report
|
|
 |
 |
Drugs of Tomorrow: Anti-asthmatics - Enter the mAbs
Datamonitor, May 2002
In-depth profiles of late stage asthma products, an overview of interesting early phase compounds and forecasted new product sales, , The anti-asthmatic market is well served by existing therapies, such as the beta2-agonists and corticosteroids opinion leaders estimate that 95% of asthma patients can be successfully treated with these agents. Consequently, to attain commercial success, pipeline products need to offer significant advantages over currently marketed therapies, particularly with respect to convenience., , This Analysis provides:, , - evaluation of new compounds in development for asthma and their ability to satisfy the unmet needs of the market , , - identification of opportunities for companies to maximize the market potential of their developmental compounds , , - assessment of the impact of novel compounds on the market positions of anti-asthmatics currently leading the market , , - forecasted sales of the key anti-asthmatics that will be launched over the period 2002 to 2009,
Customers who bought this item also bought
The 2009 Import and Export Market for Butadiene Rubber (BR) in India
The 2009 Import and Export Market for Butadiene Rubber (BR) in China
The 2009 Import and Export Market for Butadiene Rubber (BR) in Japan
The 2009 World Market Forecasts for Imported Butadiene Rubber (BR)
The 2009 World Forecasts of Butadiene Rubber (BR) Export Supplies
Chinese Markets for Polybutadiene Rubber (BR)
Stakeholder Perspectives: Asthma - Improvements to Combination Inhalers Will Satisfy a Growing Patient Base
Commercial Insight: Asthma and Copd - Combinations breathe life into the asthma and Copd markets
Stakeholder Insight: Asthma - Combination Therapy Appropriate for Everyone?
Key Trends in the Asthma and Copd Market - Uncertain times for novel inhalation devices
Drugs of Tomorrow 2001: Anticoagulants - A pipeline flowing with future blockbusters
Market Dynamics: Anti-asthmatics - Preparing for Slow Market Growth
|
 |
|
|